• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Development of novel anti-sarcoma drug based on PAI-1 regulation

Research Project

Project/Area Number 18K09096
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Review Section Basic Section 56020:Orthopedics-related
Research InstitutionTokyo Medical and Dental University

Principal Investigator

Katsushi Kikuchi  東京医科歯科大学, 大学院医歯学総合研究科, 非常勤講師 (00602062)

Co-Investigator(Kenkyū-buntansha) 佐藤 信吾  東京医科歯科大学, 医学部附属病院, 講師 (40462220)
麻生 義則  東京医科歯科大学, 大学院医歯学総合研究科, ジョイントリサーチ講座教授 (50345279)
Project Period (FY) 2018-04-01 – 2021-03-31
Project Status Completed (Fiscal Year 2020)
Budget Amount *help
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2020: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2019: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Keywords肉腫 / PAI-1 / がん幹細胞
Outline of Final Research Achievements

When the expression of PAI-1 was analyzed using qPCR method and immunostaining method using the sarcoma sample removed from the mouse sarcoma model, the expression of PAI-1 in the sarcoma was confirmed. Pai-1 inhibitors were acted on human sarcoma cell cells and human mesenchymal stem cells to analyze their effects on growth activity. As a result, it was clarified that PAI-1 inhibitors have a significant effect on cell proliferation in the sarcoma cell system in a dose-dependent manner, and that the activity is not observed in human mesenchymal stem cells. Currently, RNA-seq analysis is employed to analyze the molecular mechanism of PAI-1 inhibitors for sarcoma cells.

Academic Significance and Societal Importance of the Research Achievements

抗がん剤が大半の骨軟部肉腫に作用し難いことは、肉腫治療における大きな課題である。また、高悪性肉腫の場合は、肉眼的には完全に肉腫を切除できた場合でも、しばしば再発や転移が問題となり、このような症例は抗がん剤治療のみではコントロールができず、予後不良となる。このため、抗がん剤に代わるもしくは抗がん剤と併用する新たな肉腫治療薬が希求されている。PAI-1阻害薬はがん幹細胞ニッチからの肉腫幹細胞の離脱を促進し、抗がん剤の感受性を増強させる画期的な新規肉腫治療薬となる可能性があり、化学療法と併用することで、再発および転移の抑制を十分期待できる。

Report

(4 results)
  • 2020 Annual Research Report   Final Research Report ( PDF )
  • 2019 Research-status Report
  • 2018 Research-status Report
  • Research Products

    (4 results)

All 2021 2019

All Journal Article (1 results) (of which Int'l Joint Research: 1 results,  Peer Reviewed: 1 results,  Open Access: 1 results) Presentation (3 results) (of which Int'l Joint Research: 1 results)

  • [Journal Article] A novel PAI-1 inhibitor prevents ageing-related muscle fiber atrophy.2021

    • Author(s)
      Aihemaiti A, Yamamoto N, Piao J, Oyaizu T, Ochi H, Sato S, Okawa A, Miyata T, Tsuji K, Ezura Y, Asou Y.
    • Journal Title

      Biochem Biophys Res Commun.

      Volume: 534 Pages: 849-856

    • DOI

      10.1016/j.bbrc.2020.10.089

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Presentation] Osteocyte Sirt6 has crucial roles in bone and phosphate metabolism through senescence- dependent and -independent manner2019

    • Author(s)
      Alkebaier Aobulikasimu*1 , Hiroki Ochi1 , Jinying Piao1 , Shingo Sato1 , Kunikazu Tsuji2 , Atsushi Okawa1 , Yoshinori Asou1
    • Organizer
      米国骨代謝学会
    • Related Report
      2019 Research-status Report
    • Int'l Joint Research
  • [Presentation] PAI-1はロコモティブシンドローム、サルコペニアを加速する。2019

    • Author(s)
      アディハム アハマット  アクバル アブルカスム  越智広樹 山本尚輝  小柳津卓哉  宮田敏男 佐藤信吾  畑裕  辻邦和  大川淳  麻生義則
    • Organizer
      日本整形外科基礎学会
    • Related Report
      2019 Research-status Report
  • [Presentation] 骨細胞Sirt6による骨代謝、リン代謝制御機構2019

    • Author(s)
      Alkebaier Aobulikasimu、越智広樹、朴金瑛、佐藤信吾、辻邦和、大川淳、麻生義則
    • Organizer
      日本整形外科基礎学会
    • Related Report
      2019 Research-status Report

URL: 

Published: 2018-04-23   Modified: 2024-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi